A Phase 2 interventional study of A=Placebo and B=Inhaled Alprazolam 0.5 mg in Epilepsy, sponsored by Nova Pneuma Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by Nova Pneuma Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 793 studies in Epilepsy with a site in United States — 159 open to participants now, 194 under way, 17 of them phase 3. Epilepsy · United States.
Among the 793 studies in Epilepsy with a site in United States, this one is the 525th largest by enrollment of the 588 interventional ones that give a count, is one of 38 that started in 2015, is one of 103 in phase 2, and was the 360th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →159 of the 793 studies in Epilepsy with a site in United States are open now. Recruiting first, the newest first:
Cadence Neuroscience · Sites in United States
Ages 7+ · Men only
Duke University · Sites in United States
Ages 18–70
NeuroOne Medical Technologies Corporation · Sites in United States
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 13–29
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
793 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 82 · Phase 2 126 · Phase 3 133 · Phase 4 51
First in 1975; this study’s year is marked. 38 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 40 across the 588 interventional studies, 90 across the 193 observational. Of the 526 that completed or were terminated, 243 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
295 of 793 have an industry lead sponsor. The 10 most frequent:
Nova Pneuma Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Nova Pneuma Inc. has 1 study filed under Epilepsy — fewer than ten, so there is no comparison to draw.
72 of the studies in Epilepsy with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07010471Phase 3Praxis Precision MedicinesA Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | 2026-12 |
| NCT07019922Phase 3Praxis Precision MedicinesA Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | 2026-12 |
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT05431595Phase 3M.D. Anderson Cancer CenterManaging Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy | 2027-02-02 |
Add all 72 to your calendar (.ics) → With an account.
Among the 793 studies in Epilepsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether people who usually have photosensitive epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato Alprazolam as compared to placebo.
The purpose of this study is to determine whether people who usually have photosensitive epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato Alprazolam as compared to placebo. People with photosensitive epilepsy have changes on their electroencephalogram (EEG) when shown flashing lights. Three dose levels of Staccato Alprazolam will be compared to placebo.
This study will also assess the level of sedation of Staccato Alprazolam compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
Drug: A=Placebo · Drug: B=Inhaled Alprazolam 0.5 mg · Drug: C=Inhaled Alprazolam 1 m · Drug: D= Inhaled Alprazolam 2 mg · Drug: E=Placebo
A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
Drug: A=Placebo · Drug: B=Inhaled Alprazolam 0.5 mg · Drug: C=Inhaled Alprazolam 1 m · Drug: D= Inhaled Alprazolam 2 mg · Drug: E=Placebo
A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
Drug: A=Placebo · Drug: B=Inhaled Alprazolam 0.5 mg · Drug: C=Inhaled Alprazolam 1 m · Drug: D= Inhaled Alprazolam 2 mg · Drug: E=Placebo
A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
Drug: A=Placebo · Drug: B=Inhaled Alprazolam 0.5 mg · Drug: C=Inhaled Alprazolam 1 m · Drug: D= Inhaled Alprazolam 2 mg · Drug: E=Placebo
A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
Drug: A=Placebo · Drug: B=Inhaled Alprazolam 0.5 mg · Drug: C=Inhaled Alprazolam 1 m · Drug: D= Inhaled Alprazolam 2 mg · Drug: E=Placebo
Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR)
Photosensitivity describes the presentation of an epileptiform EEG response (photoparoxysmal response) from exposure to intermittent photic stimulation (IPS). SPR is the number of frequency steps (2, 5, 8, 10, 13, 15, 18, 20, 23, 25, 30, 40, 50 and 60 Hz). between the upper and lower limits of sensitivity to IPS for that patient at that time, in order not to evoke seizures. Thus a reduction (-change) means the intervention is working (desired effect on sensitivity)
Time frame: SPR was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred at: 10 min for alprazolam 2 mg, 1 hour for alprazolam 0.5 and 1 mg and placebo
Maximum Sedation Using Visual Analog Scale (Sedated-Alert)
Maximum change (in mm) from pretreatment baseline in level of sedation reported by the patient on a 100 mm line anchored by Sedated (0) and Alert (100)
Time frame: Sedation was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred at:: 30 min for alprazolam 1 mg, 1 hour for alprazolam 0.5 and 2 mg, and 4 hours for placebo
Maximum Sedation Using Visual Analog Scale (Sleepy-Awake)
Maximum change (in mm) from pretreatment baseline in level of sedation reported by each subject on a 100 mm line anchored by Sleepy (0) and Awake (100)
Time frame: Sleepiness was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred: at: 30 min for alprazolam 1 mg, 1 hour for alprazolam 0.5 and 2 mg and placebo
Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Standardized Photosensitivity Range (SPR)
Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on SPR (PD) for each alprazolam dose
Time frame: Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration
Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sedated-Alert)
Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sedation (PD) for each alprazolam dose
Time frame: Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration
Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sleepy-Awake)
Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sleepiness (PD) for each alprazolam dose
Time frame: Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration
| Milestone | BEADC | CDAEB | DEBAC | EDBAC | CABED |
|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 |
| Completed | 1 | 1 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Photosensitivity describes the presentation of an epileptiform EEG response (photoparoxysmal response) from exposure to intermittent photic stimulation (IPS). SPR is the number of frequency steps (2, 5, 8, 10, 13, 15, 18, 20, 23, 25, 30, 40, 50 and 60 Hz). between the upper and lower limits of sensitivity to IPS for that patient at that time, in order not to evoke seizures. Thus a reduction (-change) means the intervention is working (desired effect on sensitivity)
| Number of frequency steps | Inhaled Placebo | Staccato Alprazolam, 0.5 mg | Staccato Alprazolam, 1 mg | Staccato Alprazolam, 2 mg |
|---|---|---|---|---|
| Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR) | -0.2 (-1.87 to 1.47) | -4.4 (-6.98 to -1.82) | -5.2 (-7.85 to -2.55) | -4.8 (-7.99 to -1.61) |
Maximum change (in mm) from pretreatment baseline in level of sedation reported by the patient on a 100 mm line anchored by Sedated (0) and Alert (100)
| units on a scale | Inhaled Placebo | Staccato Alprazolam, 0.5 mg | Staccato Alprazolam, 1 mg | Staccato Alprazolam, 2 mg |
|---|---|---|---|---|
| Maximum Sedation Using Visual Analog Scale (Sedated-Alert) | -5.3 (-23.84 to 13.34) | -58 (-82.77 to -33.23) | -67.4 (-87.47 to -47.33) | -70.6 (-94.06 to -47.14) |
Maximum change (in mm) from pretreatment baseline in level of sedation reported by each subject on a 100 mm line anchored by Sleepy (0) and Awake (100)
| units on a scale | Inhaled Placebo | Staccato Alprazolam, 0.5 mg | Staccato Alprazolam, 1 mg | Staccato Alprazolam, 2 mg |
|---|---|---|---|---|
| Maximum Sedation Using Visual Analog Scale (Sleepy-Awake) | -9.2 (-26.33 to 7.93) | -54 (-72.59 to -35.31) | -58.8 (-76.01 to -41.59) | -58.8 (-69.4 to -48.2) |
Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on SPR (PD) for each alprazolam dose
| correlation coefficient | Staccato Alprazolam, 0.5 mg | Staccato Alprazolam, 1 mg | Staccato Alprazolam, 2 mg |
|---|---|---|---|
| Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Standardized Photosensitivity Range (SPR) | -0.454 ± 0.206 | -0.534 ± 0.286 | -0.410 ± 0.168 |
Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sedation (PD) for each alprazolam dose
| correlation coefficient | Staccato Alprazolam, 0.5 mg | Staccato Alprazolam, 1 mg | Staccato Alprazolam, 2 mg |
|---|---|---|---|
| Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sedated-Alert) | -0.350 ± 0.122 | -0.567 ± 0.322 | -0.623 ± 0.388 |
Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sleepiness (PD) for each alprazolam dose
| correlation coefficient | Staccato Alprazolam, 0.5 mg | Staccato Alprazolam, 1 mg | Staccato Alprazolam, 2 mg |
|---|---|---|---|
| Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sleepy-Awake) | -0.449 ± 0.201 | -0.582 ± 0.339 | -0.586 ± 0.343 |
Collected over Each subject was questioned about adverse events (AEs) at 2 min, 10 min, 30 min, 1 hr, 2 hr, 4 hr, and 6 hr post study drug administration for each study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Placebo | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Staccato® Alprazolam, 0.5 mg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Staccato® Alprazolam, 1 mg | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Staccato® Alprazolam, 2 mg | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Event | Inhaled Placebo | Staccato® Alprazolam, 0.5 mg | Staccato® Alprazolam, 1 mg | Staccato® Alprazolam, 2 mg |
|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 2/5 | 0/5 | 0/5 | 0/5 |
| DysgeusiaGastrointestinal disorders | 1/5 | 2/5 | 2/5 | 2/5 |
| Oral dysaesthesiaGastrointestinal disorders | 0/5 | 2/5 | 0/5 | 2/5 |
| SedationNervous system disorders | 0/5 | 0/5 | 1/5 | 2/5 |
| SomnolenceNervous system disorders | 1/5 | 1/5 | 2/5 | 2/5 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/5 | 2/5 | 1/5 | 2/5 |
| Eye irritationEye disorders | 1/5 | 0/5 | 0/5 | 0/5 |
| Lacrimation increasedEye disorders | 0/5 | 1/5 | 1/5 | 1/5 |
| Abdominal pain upperGastrointestinal disorders | 0/5 | 1/5 | 0/5 | 0/5 |
| RetchingGastrointestinal disorders | 0/5 | 0/5 | 0/5 | 1/5 |
All subjects treated
| Age, Continuous(years) | BEADC BEADC | CDAEB | DEBAC | EDBAC | CABED | Total |
|---|---|---|---|---|---|---|
| Mean | 24 ± 0 | 23 ± 0 | 27 ± 0 | 39 ± 0 | 23 ± 0 | 27.2 ± 6.80 |
| Sex: Female, Male(Participants) | BEADC BEADC | CDAEB | DEBAC | EDBAC | CABED | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 1 | 1 | 5 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | BEADC BEADC | CDAEB | DEBAC | EDBAC | CABED | Total |
|---|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 1 |
| Ethnicity — Not Hispanic or Latino | 1 | 1 | 1 | 1 | 0 | 4 |
| Ethnicity — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race — Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 1 |
| Race — Not Hispanic or Latino | 1 | 1 | 1 | 1 | 0 | 4 |
| Race — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | BEADC BEADC | CDAEB | DEBAC | EDBAC | CABED | Total |
|---|---|---|---|---|---|---|
| United States | 1 | 1 | 1 | 1 | 1 | 5 |
Plan to share: Yes — IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Within 10 days of request approval
Access criteria: Approval of formal request for access
Data sharing details ↗ · alexza.com
No publications or documents are linked to this record.
The record gives a start of Jan 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2021, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nova Pneuma Inc.